COVID-19 Vaccine Development for LMIC
The COVID-19 Vaccine Development for LMIC from Pfizer/BioNTech supports COVID-19 vaccine development in low and middle income countries (LMIC). The researcher and host institution must be based in an LMIC. Of particular interest are:
- Clinical studies designed to lead to approval and availability of new COVID-19 vaccine(s)
- Such vaccine(s) must be intended to protect large populations in LMIC, based on study design, GMP manufacturing capacity, product characteristics, the applicant’s ability to manage timely GCP-compliant clinical trials and regulatory filings and other relevant factors
Applicants must have a doctoral degree, e.g. PhD, MD. The support provided by Pfizer is in the form of the BNT162b2 vaccine for projects spanning 1-2 years, and no funding will be provided as part of this request for proposal. Applications are assessed on an ongoing basis with the final submission date being December 31, 2022.
Challenge: Clinical Trials
Create or sign in to your free account for more functionalities, including a full display of the eligibility criteria such as location and citizenship requirements.